Monoclonal Antibodies
SGN-B7H4V for Advanced Cancers
This trial tests a new drug called SGN-B7H4V for safety and side effects in patients with advanced or metastatic solid tumors. It aims to find the right dosage and see if the drug can effectively treat their cancer.
Monoclonal Antibodies
MK-7684A for Advanced Cancers
This trial is testing a new treatment that combines two medications to see if it works better than the current treatment for serious cancers, particularly cervical cancer. One of the medications has shown promising results in treating various cancers, including cervical cancer. The goal is to find out if this combination can improve patient outcomes by helping the immune system fight cancer more effectively.
Small Molecule Inhibitor
LY3537982 for Cancer
This trial is testing a new drug called LY3537982 in cancer patients with the KRAS G12C mutation. It targets this mutation to stop cancer cells from growing. The study includes patients who haven't responded to other treatments or cannot tolerate them. LY3537982 is a new drug targeting the KRAS G12C mutation, similar to previously approved drugs like sotorasib and adagrasib.
Immunotherapy
BMS-986340 + Nivolumab/Docetaxel for Cancer
This trial tests a new drug, BMS-986340, alone and with other cancer treatments (nivolumab and docetaxel) in patients with advanced solid tumors. The goal is to find out if it is safe and effective in treating these cancers.
Popular Filters
Trials for Ovarian Tumors Patients
Cancer Vaccine
Oregovomab + Chemo for Advanced Ovarian Cancer
This trial tests if oregovomab, an IV medication, can help treat advanced ovarian cancer when used with standard chemotherapy. It targets patients who have had surgery to remove tumors and aims to boost the immune system to fight cancer cells more effectively. Oregovomab has been previously tested in advanced ovarian cancer but did not improve outcomes.
Monoclonal Antibodies
SGN-B6A for Cancer
This trial is testing a new drug called sigvotatug vedotin alone and with other treatments to see if it is safe and effective for people with solid tumors. It will also check for any side effects. The study includes different parts to determine the best dose and to see how well the drug works alone and in combination with other treatments.
Monoclonal Antibodies
Platinum-based Therapy + Dostarlimab + Niraparib for Ovarian Cancer
This trial is designed to compare the effectiveness of the current standard of care for ovarian cancer (SOC) with or without the addition of two new potential treatments, dostarlimab and niraparib.
PARP Inhibitor
Combination Therapy for Ovarian Cancer
This trial tests niraparib alone and with other treatments in patients with ovarian, fallopian tube, or primary peritoneal cancer. It aims to see if stopping cancer cells from repairing their DNA can help treat these cancers. Niraparib is a medication taken by mouth and is approved for use in patients with recurrent ovarian, fallopian tube, or primary peritoneal cancer who have responded to previous treatments.
Genetic Testing
Screening Method for Lynch Syndrome in Endometrial and Ovarian Cancer
This trial will test a new way of identifying women with Lynch Syndrome, a hereditary disease that can lead to cancer. If successful, it could improve screening and surgery options for women at risk.
Trials for Endometrioid Adenocarcinoma Patients
Monoclonal Antibodies
SGN-B6A for Cancer
This trial is testing a new drug called sigvotatug vedotin alone and with other treatments to see if it is safe and effective for people with solid tumors. It will also check for any side effects. The study includes different parts to determine the best dose and to see how well the drug works alone and in combination with other treatments.
PARP Inhibitor
Combination Therapy for Ovarian Cancer
This trial tests niraparib alone and with other treatments in patients with ovarian, fallopian tube, or primary peritoneal cancer. It aims to see if stopping cancer cells from repairing their DNA can help treat these cancers. Niraparib is a medication taken by mouth and is approved for use in patients with recurrent ovarian, fallopian tube, or primary peritoneal cancer who have responded to previous treatments.
Genetic Testing
Screening Method for Lynch Syndrome in Endometrial and Ovarian Cancer
This trial will test a new way of identifying women with Lynch Syndrome, a hereditary disease that can lead to cancer. If successful, it could improve screening and surgery options for women at risk.
PD-L1 Inhibitor
SGN-PDL1V for Cancer
This trial is testing a new drug, SGN-PDL1V, alone and with pembrolizumab, in patients with advanced solid tumors. The goal is to see if these treatments are safe and effective. SGN-PDL1V targets cancer cells directly, while pembrolizumab helps the immune system fight the cancer.
Trials for Metastatic Patients
Cancer Vaccine
Oregovomab + Chemo for Advanced Ovarian Cancer
This trial tests if oregovomab, an IV medication, can help treat advanced ovarian cancer when used with standard chemotherapy. It targets patients who have had surgery to remove tumors and aims to boost the immune system to fight cancer cells more effectively. Oregovomab has been previously tested in advanced ovarian cancer but did not improve outcomes.
Monoclonal Antibodies
SGN-B6A for Cancer
This trial is testing a new drug called sigvotatug vedotin alone and with other treatments to see if it is safe and effective for people with solid tumors. It will also check for any side effects. The study includes different parts to determine the best dose and to see how well the drug works alone and in combination with other treatments.
Monoclonal Antibodies
Platinum-based Therapy + Dostarlimab + Niraparib for Ovarian Cancer
This trial is designed to compare the effectiveness of the current standard of care for ovarian cancer (SOC) with or without the addition of two new potential treatments, dostarlimab and niraparib.
CAR T-cell Therapy
ICT Cell Therapy for Ovarian Cancer
This trial tests a new treatment using modified immune cells (AB-1015) for patients with ovarian cancer that didn't respond to standard treatments. The modified cells are designed to target and kill cancer cells. The goal is to find a safe dose and see if the treatment helps fight the cancer. Modified immune cells, such as those used in AB-1015, have shown good curative effects in treating ovarian cancer.
Trials for BRCA1 Positive Patients
CAR T-cell Therapy
ICT Cell Therapy for Ovarian Cancer
This trial tests a new treatment using modified immune cells (AB-1015) for patients with ovarian cancer that didn't respond to standard treatments. The modified cells are designed to target and kill cancer cells. The goal is to find a safe dose and see if the treatment helps fight the cancer. Modified immune cells, such as those used in AB-1015, have shown good curative effects in treating ovarian cancer.
PARP Inhibitor
PARP Inhibitor + CTLA-4 Blockade for Ovarian Cancer
This trial is testing a combination of two drugs to treat ovarian cancer that is caused by a BRCA mutation. The drugs are a PARP inhibitor and a T cell checkpoint inhibitor. The trial is testing to see if this combination is safe and effective.
Chemotherapy
Chemotherapy + Pembrolizumab/Olaparib for Ovarian Cancer
This trial is testing a new combination of drugs to treat ovarian cancer. The new combination is pembrolizumab, carboplatin/paclitaxel, and maintenance olaparib. The hypothesis is that this new combination will be better than just carboplatin/paclitaxel at treating ovarian cancer.
Trials for BRCA2 Positive Patients
CAR T-cell Therapy
ICT Cell Therapy for Ovarian Cancer
This trial tests a new treatment using modified immune cells (AB-1015) for patients with ovarian cancer that didn't respond to standard treatments. The modified cells are designed to target and kill cancer cells. The goal is to find a safe dose and see if the treatment helps fight the cancer. Modified immune cells, such as those used in AB-1015, have shown good curative effects in treating ovarian cancer.
PARP Inhibitor
PARP Inhibitor + CTLA-4 Blockade for Ovarian Cancer
This trial is testing a combination of two drugs to treat ovarian cancer that is caused by a BRCA mutation. The drugs are a PARP inhibitor and a T cell checkpoint inhibitor. The trial is testing to see if this combination is safe and effective.
Phase 3 Trials
Cancer Vaccine
Oregovomab + Chemo for Advanced Ovarian Cancer
This trial tests if oregovomab, an IV medication, can help treat advanced ovarian cancer when used with standard chemotherapy. It targets patients who have had surgery to remove tumors and aims to boost the immune system to fight cancer cells more effectively. Oregovomab has been previously tested in advanced ovarian cancer but did not improve outcomes.
Monoclonal Antibodies
Platinum-based Therapy + Dostarlimab + Niraparib for Ovarian Cancer
This trial is designed to compare the effectiveness of the current standard of care for ovarian cancer (SOC) with or without the addition of two new potential treatments, dostarlimab and niraparib.
Trials With No Placebo
Monoclonal Antibodies
SGN-B6A for Cancer
This trial is testing a new drug called sigvotatug vedotin alone and with other treatments to see if it is safe and effective for people with solid tumors. It will also check for any side effects. The study includes different parts to determine the best dose and to see how well the drug works alone and in combination with other treatments.
PARP Inhibitor
Combination Therapy for Ovarian Cancer
This trial tests niraparib alone and with other treatments in patients with ovarian, fallopian tube, or primary peritoneal cancer. It aims to see if stopping cancer cells from repairing their DNA can help treat these cancers. Niraparib is a medication taken by mouth and is approved for use in patients with recurrent ovarian, fallopian tube, or primary peritoneal cancer who have responded to previous treatments.
Genetic Testing
Screening Method for Lynch Syndrome in Endometrial and Ovarian Cancer
This trial will test a new way of identifying women with Lynch Syndrome, a hereditary disease that can lead to cancer. If successful, it could improve screening and surgery options for women at risk.
CAR T-cell Therapy
ICT Cell Therapy for Ovarian Cancer
This trial tests a new treatment using modified immune cells (AB-1015) for patients with ovarian cancer that didn't respond to standard treatments. The modified cells are designed to target and kill cancer cells. The goal is to find a safe dose and see if the treatment helps fight the cancer. Modified immune cells, such as those used in AB-1015, have shown good curative effects in treating ovarian cancer.
CAR T-cell Therapy
TC-510 Cell Therapy for Cancer
This trial tests TC-510, a therapy using a patient's own modified T cells to target and attack cancer cells. It is aimed at patients with cancers that are hard to treat with standard methods. The modified T cells are designed to recognize specific proteins on cancer cells and get an extra boost to kill them.
View More Related Trials
Frequently Asked Questions
Introduction to ovarian cancer
What are the top hospitals conducting ovarian cancer research?
When it comes to cutting-edge clinical trials in the battle against ovarian cancer, several top hospitals are making significant strides. In Houston, M D Anderson Cancer Center stands out with 11 ongoing trials dedicated to ovarian cancer and an impressive record of 49 completed studies since their first trial in 2003. Massachusetts General Hospital in Boston is also at the forefront, currently conducting 10 active ovarian cancer trials and having amassed a total of 56 trials over time since they began investigating this disease back in 2002.
Meanwhile, Memorial Sloan Kettering Cancer Center in New york has made substantial contributions as well. They have six ongoing ovarian cancer trials and have conducted a noteworthy total of 60 trials since recording their inaugural study in 1994. On the West Coast, Kaiser Permanente Los Angeles Medical Center takes part with six active ovarian cancer trials while they've accumulated eleven previous investigations; their commitment started relatively recently with their first recorded trial taking place just sixteen years agoin2005.
Additionally adding itself to this list is Mayo Clinic located at Arizona's Scottsdale where there are aroundsixongoing clinical tests concerningovarian carcinoma while fifteencompleted experiments priorly wereconducted by them within thatfieldw
Which are the best cities for ovarian cancer clinical trials?
Los Angeles, California; New york, New York; and Boston, Massachusetts are notable cities for ovarian cancer clinical trials. Los Angeles has 37 active trials investigating treatments like Paclitaxel, Bevacizumab, and Cisplatin. In New York City, there are 36 ongoing studies focused on BMS-986340, Paclitaxel, LY3537982 among others. Meanwhile in Boston researchers are conducting 36 active trials exploring Olaparib 300mg tablets, Dendritic Cell/Tumor Fusion Vaccine and Bevacizumab as potential treatment options. These cities offer individuals with ovarian cancer access to cutting-edge clinical trials and potential breakthroughs in care.
Which are the top treatments for ovarian cancer being explored in clinical trials?
Clinical trials are at the forefront of advancing treatments for ovarian cancer, with several promising options currently under exploration. Paclitaxel, a well-established drug since 1999, is being tested in five active trials and has participated in an impressive 155 all-time ovarian cancer trials. Another contender making waves is niraparib, introduced in 2015 and currently involved in five ongoing trials along with a track record of 45 all-time studies for ovarian cancer. Additionally, bevacizumab shows promise with its involvement in five active clinical trials and participation in 80 all-time ovarian cancer trials since its introduction back in 2003. Lastly, carboplatin remains relevant after two decades since first listed; it is currently participating in three active clinical trials while having been included across an extensive history of 141 all-time ovarian cancer studies. These innovative developments hold great potential to improve outcomes for individuals battling this complex disease.
What are the most recent clinical trials for ovarian cancer?
Exciting advancements in ovarian cancer research offer hope for improved treatment options. Recent clinical trials have explored various approaches to tackle this disease. One such trial, Part II Multiple Participant Cohort RO7515629 Dose Escalation, combines Phase 1 and Phase 2 studies to investigate the effectiveness of a new therapy for ovarian cancer patients. Another study focuses on AB-1015, a potential treatment that has entered Phase 1 testing with encouraging results so far. Additionally, SGN-PDL1V is being evaluated in a Phase 1 trial as a targeted therapy specifically designed for ovarian cancer patients. Paclitaxel is also under investigation in a Phase 2 study aiming to gain further insights into its efficacy against ovarian cancer. With these ongoing trials and their promising findings, there is renewed optimism surrounding the future of ovarian cancer treatments.
What ovarian cancer clinical trials were recently completed?
Several clinical trials for ovarian cancer have recently reached completion, demonstrating progress in the pursuit of improved treatments. Among them is a trial sponsored by Astellas Pharma Global Development, Inc., investigating ASP0739, which concluded in January 2022. Additionally, the Masonic Cancer Center at the University of Minnesota completed a trial evaluating Enoblituzumab in April 2021. Furthermore, Rucaparib was studied in a trial sponsored by pharmaand GmbH and finished its course in March 2021. These recent advancements signify the ongoing efforts to combat ovarian cancer and provide hope for patients facing this challenging disease.